Advertisement

Evaluation of corneal cross-linking as adjuvant therapy for the management of fungal keratitis

  • Wei Anji 
  • Wang Kaidi 
  • Wang Yan 
  • Gong Lan 
  • Xu Jianjiang 
  • Shao Tingting Email author
Cornea
  • 69 Downloads

Abstract

Purpose

To evaluate the efficacy of corneal cross-linking (CXL) as adjuvant therapy for the treatment of fungal ulcerative keratitis.

Methods

Forty-one patients with fungal ulcerative keratitis were recruited and assigned into two randomized controlled groups. These groups were treated with CXL combined with antifungal medications (CXL-M) or antifungal medications alone (M). The ulcers were assessed by slit-lamp biomicroscopy, slit-lamp images, in vivo confocal microscopy (IVCM), and anterior segment optical coherence tomography (AS-OCT). The patients were followed up before surgery/first visit (FV), 1 day after surgery, 1 and 2 weeks, and 1, 2, 3, 4, 5, and 6 months after surgery/FV.

Results

In the cured patients, the area of corneal ulcers, the duration of ulcer healing, the time to non-observed fungal hyphae by IVCM, the number of antifungal medications, the frequency of administered medications, and the maximum ulcer depth decreased significantly after CXL (all P < 0.05) compared with the M group. There were no significant differences in either corneal thickness or epithelial thickness of ulcers after healing between 5 and 6 months after surgery in the CXL-M group, while these were increased significantly at 6 months compared with 5 months after FV in the M group (both P < 0.05).

Conclusions

In our study, CXL accelerated healing of the fungal ulcers, shortened the treatment duration, and minimized the need for medications and surgery. It appears that CXL is an effective procedure and adjuvant therapy for managing fungal keratitis.

Keywords

Corneal cross-linking Fungal keratitis Riboflavin Ultraviolet A (UV-A) 

Notes

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 81300759).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kernt M, Kampik A (2009) Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology 258:84–93.  https://doi.org/10.1016/j.tox.2009.01.008 CrossRefGoogle Scholar
  2. 2.
    Wu J, Zhang WS, Zhao J, Zhou HY (2016) Review of clinical and basic approaches of fungal keratitis. Int J Ophthalmol 9:1676–1683.  https://doi.org/10.18240/ijo.2016.11.23 Google Scholar
  3. 3.
    Prajna NV, Srinivasan M, Lalitha P, Krishnan T, Rajaraman R, Ravindran M, Mascarenhas J, Oldenburg CE, Ray KJ, McLeod SD, Acharya NR, Lietman TM (2013) Differences in clinical outcomes in keratitis due to fungus and bacteria. JAMA Ophthalmol 131:1088–1089.  https://doi.org/10.1001/jamaophthalmol.2013.1612 CrossRefGoogle Scholar
  4. 4.
    Fini ME, Cook JR, Mohan R (1998) Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res 290 Suppl:S12–S23CrossRefGoogle Scholar
  5. 5.
    Anwar HM, El-Danasoury AM, Hashem AN (2011) Corneal collagen crosslinking in the treatment of infectious keratitis. Clin Ophthalmol 5:1277–1280.  https://doi.org/10.2147/OPTH.S24532 CrossRefGoogle Scholar
  6. 6.
    Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R, Cano M, Dick J, Behrens A (2008) Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 49:3402–3408.  https://doi.org/10.1167/iovs.07-1592 CrossRefGoogle Scholar
  7. 7.
    Kimakura M, Usui T, Yokoo S, Nakagawa S, Yamagami S, Amano S (2014) Toxicity of topical antifungal agents to stratified human cultivated corneal epithelial sheets. J Ocul Pharmacol Ther 30:810–814.  https://doi.org/10.1089/jop.2014.0044 CrossRefGoogle Scholar
  8. 8.
    Baier J, Maisch T, Maier M, Engel E, Landthaler M, Baumler W (2006) Singlet oxygen generation by UVA light exposure of endogenous photosensitizers. Biophys J 91:1452–1459.  https://doi.org/10.1529/biophysj.106.082388 CrossRefGoogle Scholar
  9. 9.
    Garg P, Das S, Roy A (2017) Collagen cross-linking for microbial keratitis. Middle East Afr J Ophthalmol 24:18–23.  https://doi.org/10.4103/meajo.MEAJO_305_16 Google Scholar
  10. 10.
    Kymionis GD, Mikropoulos DG, Portaliou DM, Voudouragkaki IC, Kozobolis VP, Konstas AG (2013) An overview of corneal collagen cross-linking (CXL). Adv Ther 30:858–869.  https://doi.org/10.1007/s12325-013-0065-9 CrossRefGoogle Scholar
  11. 11.
    Alhayek A, Lu PR (2015) Corneal collagen crosslinking in keratoconus and other eye disease. Int J Ophthalmol 8:407–418.  https://doi.org/10.3980/j.issn.2222-3959.2015.02.35 Google Scholar
  12. 12.
    O'Brart DP, Patel P, Lascaratos G, Wagh VK, Tam C, Lee J, O'Brart NA (2015) Corneal cross-linking to halt the progression of keratoconus and corneal ectasia: seven-year follow-up. Am J Ophthalmol 160:1154–1163.  https://doi.org/10.1016/j.ajo.2015.08.023 CrossRefGoogle Scholar
  13. 13.
    Li G, Fan ZJ, Peng XJ (2012) Corneal collagen crosslinking for corneal ectasia of post-LASIK: one-year results. Int J Ophthalmol 5:190–195.  https://doi.org/10.3980/j.issn.2222-3959.2012.02.15 Google Scholar
  14. 14.
    Sharma N, Roy S, Maharana PK, Sehra SV, Sinha R, Tandon R, Titiyal JS, Vajpayee RB (2014) Outcomes of corneal collagen crosslinking in pseudophakic bullous keratopathy. Cornea 33:243–246.  https://doi.org/10.1097/ICO.0000000000000004 CrossRefGoogle Scholar
  15. 15.
    Alshehri JM, Caballero-Lima D, Hillarby MC, Shawcross SG, Brahma A, Carley F, Read ND, Radhakrishnan H (2016) Evaluation of corneal cross-linking for treatment of fungal keratitis: using confocal laser scanning microscopy on an ex vivo human corneal model. Invest Ophthalmol Vis Sci 57:6367–6373.  https://doi.org/10.1167/iovs.16-20110 CrossRefGoogle Scholar
  16. 16.
    Goodrich RP (2000) The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78(Suppl 2):211–215Google Scholar
  17. 17.
    Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T (2008) Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea 27:590–594.  https://doi.org/10.1097/ICO.0b013e318169d698 CrossRefGoogle Scholar
  18. 18.
    Igal V, Pikkel Igal YS, Pikkel YY (2017) Corneal cross-linking as a treatment for fungal keratitis associated with corneal melting. Case Rep Ophthalmol 8:148–151.  https://doi.org/10.1159/000456537 CrossRefGoogle Scholar
  19. 19.
    Shetty R, Nagaraja H, Jayadev C, Shivanna Y, Kugar T (2014) Collagen crosslinking in the management of advanced non-resolving microbial keratitis. Br J Ophthalmol 98:1033–1035.  https://doi.org/10.1136/bjophthalmol-2014-304944 CrossRefGoogle Scholar
  20. 20.
    Li Z, Jhanji V, Tao X, Yu H, Chen W, Mu G (2013) Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol 97:669–671.  https://doi.org/10.1136/bjophthalmol-2012-302518 CrossRefGoogle Scholar
  21. 21.
    Mohan M, Panda A, Gupta SK (1989) Management of human keratomycosis with miconazole. Aust N Z J Ophthalmol 17:295–297CrossRefGoogle Scholar
  22. 22.
    Shi W, Li S, Liu M, Jin H, Xie L (2008) Antifungal chemotherapy for fungal keratitis guided by in vivo confocal microscopy. Graefes Arch Clin Exp Ophthalmol 246:581–586.  https://doi.org/10.1007/s00417-007-0719-x CrossRefGoogle Scholar
  23. 23.
    Das S, Samant M, Garg P, Vaddavalli PK, Vemuganti GK (2009) Role of confocal microscopy in deep fungal keratitis. Cornea 28:11–13.  https://doi.org/10.1097/ICO.0b013e318181cff7 CrossRefGoogle Scholar
  24. 24.
    Campoy S, Adrio JL (2017) Antifungals. Biochem Pharmacol 133:86–96.  https://doi.org/10.1016/j.bcp.2016.11.019 CrossRefGoogle Scholar
  25. 25.
    Wang JY, Wang DQ, Qi XL, Cheng J, Xie LX (2018) Modified ulcer debridement in the treatment of the superficial fungal infection of the cornea. Int J Ophthalmol 11:223–229.  https://doi.org/10.18240/ijo.2018.02.07 Google Scholar
  26. 26.
    Xie L, Zhai H, Shi W (2007) Penetrating keratoplasty for corneal perforations in fungal keratitis. Cornea 26:158–162.  https://doi.org/10.1097/01.ico.0000248381.24519.0d CrossRefGoogle Scholar
  27. 27.
    Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW, Jr. (2012) Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg 28: 706–713 DOI  https://doi.org/10.3928/1081597X-20120921-06
  28. 28.
    Ozdemir HB, Kalkanci A, Bilgihan K, Gocun PU, Ogut B, Karakurt F, Erdogan M (2018) Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis. Acta Ophthalmol.  https://doi.org/10.1111/aos.13829
  29. 29.
    Kimura K, Orita T, Nomi N, Fujitsu Y, Nishida T, Sonoda KH (2012) Identification of common secreted factors in human corneal fibroblasts exposed to LPS, poly(I:C), or zymosan. Exp Eye Res 96:157–162.  https://doi.org/10.1016/j.exer.2011.10.015 CrossRefGoogle Scholar
  30. 30.
    Vajpayee RB, Shafi SN, Maharana PK, Sharma N, Jhanji V (2015) Evaluation of corneal collagen cross-linking as an additional therapy in mycotic keratitis. Clin Exp Ophthalmol 43:103–107.  https://doi.org/10.1111/ceo.12399 CrossRefGoogle Scholar
  31. 31.
    Papaioannou L, Miligkos M, Papathanassiou M (2016) Corneal collagen cross-linking for infectious keratitis: a systematic review and meta-analysis. Cornea 35:62–71.  https://doi.org/10.1097/ICO.0000000000000644 CrossRefGoogle Scholar
  32. 32.
    Spoerl E, Wollensak G, Seiler T (2004) Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res 29:35–40.  https://doi.org/10.1080/02713680490513182 CrossRefGoogle Scholar
  33. 33.
    Hovakimyan M, Guthoff RF, Stachs O (2012) Collagen cross-linking: current status and future directions. J Ophthalmol 2012:406850.  https://doi.org/10.1155/2012/406850 CrossRefGoogle Scholar
  34. 34.
    Wang F (2008) UVA/riboflavin-induced apoptosis in mouse cornea. Ophthalmologica 222:369–372.  https://doi.org/10.1159/000151247 CrossRefGoogle Scholar
  35. 35.
    Pouget JP, Douki T, Richard MJ, Cadet J (2000) DNA damage induced in cells by gamma and UVA radiation as measured by HPLC/GC-MS and HPLC-EC and Comet assay. Chem Res Toxicol 13:541–549CrossRefGoogle Scholar
  36. 36.
    Hiraku Y, Ito K, Hirakawa K, Kawanishi S (2007) Photosensitized DNA damage and its protection via a novel mechanism. Photochem Photobiol 83:205–212.  https://doi.org/10.1562/2006-03-09-IR-840 CrossRefGoogle Scholar
  37. 37.
    Wollensak G, Spoerl E, Reber F, Seiler T (2004) Keratocyte cytotoxicity of riboflavin/UVA-treatment in vitro. Eye (Lond) 18:718–722.  https://doi.org/10.1038/sj.eye.6700751 CrossRefGoogle Scholar
  38. 38.
    Wollensak G, Sporl E, Reber F, Pillunat L, Funk R (2003) Corneal endothelial cytotoxicity of riboflavin/UVA treatment in vitro. Ophthalmic Res 35:324–328 DOI 74071CrossRefGoogle Scholar
  39. 39.
    Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T (2007) Safety of UVA-riboflavin cross-linking of the cornea. Cornea 26:385–389.  https://doi.org/10.1097/ICO.0b013e3180334f78 CrossRefGoogle Scholar
  40. 40.
    Mazzotta C, Balestrazzi A, Traversi C, Baiocchi S, Caporossi T, Tommasi C, Caporossi A (2007) Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans. Cornea 26:390–397.  https://doi.org/10.1097/ICO.0b013e318030df5a CrossRefGoogle Scholar
  41. 41.
    Hafezi F (2011) Limitation of collagen cross-linking with hypoosmolar riboflavin solution: failure in an extremely thin cornea. Cornea 30:917–919.  https://doi.org/10.1097/ICO.0b013e31820143d1 CrossRefGoogle Scholar
  42. 42.
    Raiskup F, Spoerl E (2013) Corneal crosslinking with riboflavin and ultraviolet A. Part II. Clinical indications and results. Ocul Surf 11:93–108.  https://doi.org/10.1016/j.jtos.2013.01.003 CrossRefGoogle Scholar
  43. 43.
    Rahman MR, Johnson GJ, Husain R, Howlader SA, Minassian DC (1998) Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol 82:919–925CrossRefGoogle Scholar
  44. 44.
    Foster CS, Lass JH, Moran-Wallace K, Giovanoni R (1981) Ocular toxicity of topical antifungal agents. Arch Ophthalmol 99:1081–1084CrossRefGoogle Scholar
  45. 45.
    Allan BD, Dart JK (1995) Strategies for the management of microbial keratitis. Br J Ophthalmol 79:777–786CrossRefGoogle Scholar
  46. 46.
    Zloty P, Villavicencio O, Belin MW (2013) Aggressive debridement improves outcome of fungal keratitis. Asia Pac J Ophthalmol (Phila) 2:217–220.  https://doi.org/10.1097/APO.0b013e3182993f4b CrossRefGoogle Scholar
  47. 47.
    McGrath LA, Lee GA (2014) Techniques, indications and complications of corneal debridement. Surv Ophthalmol 59:47–63.  https://doi.org/10.1016/j.survophthal.2013.03.004 CrossRefGoogle Scholar
  48. 48.
    Chan E, Snibson GR, Sullivan L (2014) Treatment of infectious keratitis with riboflavin and ultraviolet-A irradiation. J Cataract Refract Surg 40:1919–1925.  https://doi.org/10.1016/j.jcrs.2014.09.001 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Wei Anji 
    • 1
  • Wang Kaidi 
    • 1
  • Wang Yan 
    • 1
  • Gong Lan 
    • 1
  • Xu Jianjiang 
    • 1
  • Shao Tingting 
    • 1
    Email author
  1. 1.Department of Ophthalmology, Eye, Ear, Nose, and Throat Hospital, School of Shanghai MedicineFudan UniversityShanghaiChina

Personalised recommendations